Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12137190 | 0.89 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HRH2HRH1HRH3 | |
| SCHEMBL14116872 | 0.85 | CYP3A4 (0.47) | ALDH1A1SMN1; SMN2HRH2HRH1KDM4E | |
| SCHEMBL23634802 | 0.84 | HRH2 (0.46) | ALDH1A1SMN1; SMN2HRH2HRH1HRH3 | |
| SCHEMBL8221324 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2HRH2HRH1HRH3 | |
| SCHEMBL10924619 | 0.82 | ALDH1A1 (0.39) | ALDH1A1HRH3KDM4E | |
| SCHEMBL11575418 | 0.82 | — | — | |
| SCHEMBL12793973 | 0.81 | HRH2 (0.47) | ALDH1A1SMN1; SMN2HRH2HRH1HRH3 | |
| SCHEMBL1100792 | 0.79 | KDM1A (0.43) | ALDH1A1SMN1; SMN2HRH2HRH1HRH3 | |
| SCHEMBL14670865 | 0.79 | PTGS2 (0.54) | HRH2HRH1HRH3KDM1AKDM4E | |
| SCHEMBL15295188 | 0.78 | HRH2 (0.44) | ALDH1A1SMN1; SMN2HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2203457-B1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-8067620-B2 | Cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ439); nonneurotoxic; pharmacokinetics; stability; oral absorption; bioavailability; anticarcinogenic agents; single-dose cure;antiprotozoan agents; parasiticides; schistosomiasis; | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067620-B2 | Cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ439); nonneurotoxic; pharmacokinetics; stability; oral absorption; bioavailability; anticarcinogenic agents; single-dose cure;antiprotozoan agents; parasiticides; schistosomiasis; | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2011-11-29 | — | — | US | disclosed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2009058859-A2 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2009-05-07 | — | — | WO | disclosed |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | ALDH1A1 3704/4885SMN1; SMN2 1354/4885HRH2 406/4885 |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | ALDH1A1 3704/4885SMN1; SMN2 1354/4885HRH2 406/4885 |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | DHODH, THPO, SQLE | ALDH1A1 319/4885SMN1; SMN2 2799/4885HRH2 3772/4885 |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK5 | ALDH1A1 3615/4885SMN1; SMN2 1288/4885HRH2 366/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | ALDH1A1 3704/4885SMN1; SMN2 1354/4885HRH2 406/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | ALDH1A1 3405/4885SMN1; SMN2 3321/4885HRH2 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.